We came across a bullish thesis on Biohaven Ltd. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on BHVN. Biohaven Ltd.'s share was trading at $11.54 as of February 18th.
[caption id="attachment_570725" align="aligncenter" width="750"]Biohaven Ltd. is a clinical-stage biotechnology company targeting large global markets with significant unmet needs across neurology, immunology, and oncology, with lead programs such as its Kv7 activator franchise representing potential blockbuster...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.